Description
A gemcitabine phosphoramidate prodrug that can overcome the key cancer resistance; NUC-1031 is significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it is resistant to cytidine deaminase-mediated degradation compared with gemcitabine; inhibits L1210 and BxPC-3 cell proliferation with IC50 of 35nM and 150nM, respectively; significantly reduces tumor volumes in vivo in pancreatic cancer xenografts. Pancreatic Cancer Phase 3 Clinical